Biomaterials Market size is projected to grow from USD 45.46 billion to USD 101.53 billion, reflecting a CAGR of over 6.5% during the forecast period, between 2025 and 2037. In the year 2025, the industry size of biomaterials is estimated at USD 47.79 billion.
The growing prevalence of musculoskeletal and chronic skeletal medical conditions and rising research on regenerative medicine are expected to propel the biomedical materials market growth. About 17.1 billion people are suffering from musculoskeletal conditions across the world in 2022.
Growth Drivers
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
6.5% |
Base Year Market Size (2024) |
USD 45.46 billion |
Forecast Year Market Size (2037) |
USD 101.53 billion |
Regional Scope |
|
Type of Materials (Metallic, Ceramic, Polymer, Natural)
The metallic biomaterials segment is set to account for largest biomaterials market share by the end of 2037, on the back of growing funds, and grants by government bodies and universities for the development of novel biomaterials. Also, rising geriatric population across the world is anticipated to fuel the market growth owing to the increased use of biomaterials in drug delivery, tissue repair, and regeneration of bone. The geriatric population with the age 60 years and over increased from 1 billion in 2020 and reached 1.4 billion in 2022 across the world.
Our in-depth analysis of the global biomaterials market includes the following segments:
By Type of Materials |
|
By Application |
|
The market in the North American region is poised to hold largest share by the end of 2037, owing to rising healthcare infrastructure, growing diabetic population, highest population pool, increasing healthcare sector in emerging economies, and rising healthcare expenditure. The number of people suffering from diabetes across the world increased by 3% during 2000-2019.
Olympus Corporation declared the acquisition of FH ORTHO SAS, to build its portfolio on novel solutions to use in MIS procedures in ligament repair and foot, ankle, and trauma surgery.
FDA NEWS designated the Bonalive biomaterials’ bone graft substitute as Breakthrough Device. The orthopedic granules of the substitute are made of bioactive glass used to fill bony voids and gaps to protect against microbial colonization during the bone healing process.
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?